Grand Rounds | 2022-2023

A THI EDUCATION TRADITION

Commitment to Learning & Professional Fellowship

Since its founding in 1962, THI has remained dedicated to improving the standard of care and advancing knowledge through cardiovascular education and research.  Texas Heart Institute Grand Rounds is an esteemed tradition that attracts leading experts from around the world each year. Texas Heart Institute Grand Rounds is hosted in the Denton A. Cooley Auditorium at 6770 Bertner Avenue in Houston, TX.

Series attendees include cardiology fellows and faculty, members of the Departments of Internal Medicine and Cardiovascular Surgery, as well as visitors from other clinical and teaching institutions in the Texas Medical Center. Grand Rounds is livebroadcasted for online viewing on any desktop computer or mobile device.  

A Continuing Medical Education Activity

Accreditation and Credit Designation

Texas Heart Institute Cardiology Grand Rounds provides a weekly opportunity to learn from leading medical and surgical experts, sharing the latest advancements and innovations in the diagnosis, treatment, and prevention of cardiovascular disease. Located in the Denton A. Cooley Auditorium, THI offers CME credits for participation in Grand Rounds. Attendees can also log in from any computer, phone, or tablet to participate in the Live Webcast.


Texas Heart Institute is accredited by the Accreditation Council or Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Texas Heart Institute designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Texas Heart Institute
Houston, TX

Director, Thoracic Surgical ICU & ECMO Program
Baylor St. Luke's Medical Center
Houston, TX

Professor of Surgery at the University of Toronto
Melanie Munk Chair of Cardiovascular Surgery at the Peter Munk Cardiac Centre
Toronto, Canada

Texas Heart Institute
Houston, TX

Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Herman B Wells Center for Pediatric Research, Cardiac Developmental Biology
Indiana University School of Medicine
Indianapolis, IN

University of Arizona College of Medicine
Tucson, AZ

Morton J. Kern, MD, MSCAI, FAHA, FACC

University of California, Irvine Medical Center
Orange, CA

National Heart Centre Singapore

University of California, San Francisco
San Francisco, CA

Baptist Health Medical Group
Louisville, KY

University of Texas Southwestern Medical Center
Dallas, TX

Advanced Cardiovascular & Vascular Centers
Grand Rapids, MI

Baylor College of Medicine
Houston, TX

Massachusetts General Hospital
Boston, MA

Monash University
Melbourne, Australia

Icahn School of Medicine at Mount Sinai
New York, NY

Assistant Professor, Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Baylor College of Medicine
Texas Heart Institute
Baylor Saint Luke's Medical Center
Houston, TX

Duke University School of Medicine
Durham, NC

Texas Heart Institute
Houston, TX

Northwestern University Feinberg School of Medicine
Evanston, IL

Massachusetts General Hospital
Boston, MA

Professor of Medicine - Cardiology
Cardiovascular Disease Fellowship Program Director
Baylor College of Medicine
Houston, TX

Staff Cardiologist
Co-Director, VA Advanced Fellowship Program in Health Services Research & Development
Michael E. DeBakey Veterans Affairs Medical Center
Houston, TX

University of South Florida College of Medicine
University of South Florida Heart Institute
Tampa, FL

September 16 | John M. Mandrola, MD | Putting Dogmas of Cardiology to the Test

Putting Dogmas of Cardiology to the Test

John M. Mandrola, MD
Cardiology & Electrophysiology
Baptist Health

Overview:

While the field of cardiology has been exemplary in the generation of evidence, much of what we now accept as therapeutic fashion comes with weak evidentiary support. My goal is to use historical lessons as a means to render learners less susceptible to dogma and medical reversals.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Use seminal trials to guide current critical appraisal
  • Resist the urge to accept practices with weak evidentiary support
  • Use critical appraisal skills to reset prior beliefs about what does and does not benefit patients

Disclosures:

John Mandrola, MD has nothing to disclose relevant to the content of his presentation

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

September 23 | Paolo E. Angelini, MD | Takotsubo Cardiomyopathy: Can We Finally Clarify its Cause and Pathophysiology?

Takotsubo Cardiomyopathy: Can We Finally Clarify its Cause and Pathophysiology?

Paolo E. Angelini, MD
Interventional Cardiology
Texas Heart Institute

 

Overview:

Takotsubo cardiomyopathy (TTC) is a persistently confusing condition especially affecting women.

Its causes and most effective treatment are still unclear.  We have developed at Texas heart institute a novel theory based on endothelial dysfunction and coronary spasm.  We have substantial objective evidence now to claim that TTC can finally be reproduced in the Cath lab by acetylcholine testing of endothelial dysfunction and that intracoronary nitroglycerine can reliably abort the presentation.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Discuss the condition to establish the individual patient liability to Takotsubo is endothelial dysfunction. Acetylcholine testing can reproduce this entity during heart catheterization. Catecholamine surge can be a non-essential precipitating cause in predisposed patients.
  • Discuss Nitroglycerine that can apparently abort Takotsubo if given early in its onset. Long term Calcium antagonists can apparently be successful in preventing relapsing.

Disclosures:

Paolo E. Angelini, MD has nothing to disclose relevant to this program.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

September 30 | Ourania Preventza, MD, MBA, FACS | Current Management of Acute Type B Aortic Dissection


Current Management of Acute Type B Aortic Dissection

Ourania Preventza, MD
Cardiothoracic Surgery
Baylor St Luke’s Medical Center

 

Overview:

We will discuss current management of acute Type B aortic dissection: Pros and cons of medical and surgical management

Objectives:

At the conclusion of the activity a participant should be able to:

  • Review the latest advances and management of acute Type B aortic dissection
  • Discuss the pros and cons of medical versus surgical treatment

Disclosures:

Ourania Preventza, MD is a consultant for W. L. Gore and Terumo.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

October 7 | Subhasis Chatterjee, MD, FACS | ECMO for COVID-19: Collaborative Experience from the TMC

Director, Thoracic Surgical ICU & ECMO Program
Baylor St. Luke’s Medical Center
Houston, TX

 

Overview:

We will review of worldwide outcomes of ECMO for COVID-19 and our institutional and TMC opportunities for collaboration with ECMO

Objectives:

At the conclusion of the activity a participant should be able to:

  • Summarize indications and outcomes for ECMO in COVID-19 respiratory failure
  • Demonstrate opportunities for collaborative during the COVID-19 pandemic
  • Evaluate sustainable lessons from the COVID-19 ECMO experience

Disclosures:

Subhasis Chatterjee, MD is on advisory board for Edwards Lifesciences, La Jolla Pharmaceuticals, Baxter Pharmaceuticals, and Eagle Pharmaceuticals.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

 Accreditation:

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

October 14 | Salim Virani, MD, PhD, FACC, FAHA, FASPC | Lipid Lowering Therapies: Where Did We Start, Where We are Now, and What Does the Future Hold?

Professor of Medicine – Cardiology
Cardiovascular Disease Fellowship Program Director
Baylor College of Medicine
Houston, TX

Staff Cardiologist
Co-Director, VA Advanced Fellowship Program in Health Services Research & Development
Michael E. DeBakey Veterans Affairs Medical Center
Houston, TX

 

Overview:

This presentation will provide clinicians with a history and an overview of lipid lowering therapies from statin therapies to non-statin LDL lowering therapies including ezetimibe, PCSK9 inhibitors, inclisiran. We will also discuss triglyceride lowering therapies as well as therapies on horizon to lower lipoprotein (a). We will also discuss what does the future hold for lipid lowering therapies including gene editing and how those can be personalized.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Describe the role of lipid lowering therapies in atherosclerotic cardiovascular disease (ASCVD) risk reduction
  • Effectively integrate the use of statin and non-statin lipid lowering therapies in their clinical practice
  • Describe the role of emerging lipid lowering therapies in lowering ASCVD risk

Disclosures:

Salim S. Virani, MD, PhD has nothing to disclose relevant to the content of his presentation

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation:

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

October 21 | Anthony B. Firulli, PhD | Building a Heart HAND by HAND

Herman B Wells Center for Pediatric Research, Cardiac Developmental Biology
Indiana University School of Medicine
Indianapolis, IN

 

Overview:

We will discuss the most recent data on the role of Hand Factors in heart and embryonic development

Objectives:

At the conclusion of the activity a participant should be able to:

  • Review some of the gene regulatory network functions of Hand factors

Disclosures:

Anthony Firulli, PhD is an advisor for Additional Ventures

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

Accreditation:

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

October 28 | Ambarish Pandey, MD, MS, FAHA | Rethinking Hospital Rankings: From Policy-Based Evidence to Evidence-Based Policy

Assistant Professor, Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX

 

Overview:

We will discuss the novel risk prediction approaches for heart failure in diabetes, including role of Machine learning models, cardiac biomarkers, and optimal implementation strategy for real-world practice. We will also discuss how such approaches can help allocate evidence based therapies to the highest risk individuals.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Use risk alogrithms for heart failure risk prediction in diabetes
  • Identify risk factors for heart failure in diabetes
  • Identify therapies that can be used to prevent heart failure in diabetes

Disclosures:

Ambarish Pandey, MD is a consultant for Tricog Health, Rivus, Roche and Cytokinetics.  He owns stocks for consulting service Palomarin Inc.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

Accreditation:

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

THURSDAY November 3 | Carolyn Lam, MBBS, PHD, FRCP, FAMS, FACC, FESC | Heart Failure with Preserved Ejection Fraction (HFpEF): Past, Present, Future

Carolyn Lam, MD, PhD

Professor, Duke-National University of Singapore
Senior Consultant, Department of Cardiology and Director of Women’s Heart Health
National Heart Centre Singapore

 

Overview:

This lecture traces the development of understanding HFpEF and its treatment over the years; and what are the current and future management of HFpEF.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Describe the evolution of nomenclature and mechanistic understanding of HFpEF
  • Review treatment approaches that have and have not worked in HFpEF
  • Explain recent developments and their implications for future management of HFpEF

 Disclosures:

Carolyn Lam, MD, PhD is a consultant or on the advisory board for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai.  She receives research grant support for Bayer and Roche Diagnostics.  She is also co-founder and non-executive director forf US2.ai.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

All relevant financial relationships have been mitigated.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

November 11 | NO GRAND ROUNDS | THI Cardiac Society Symposium

November 18 | Robert H. Lustig, MD, MSL | Cariology and Cardiology: Chronic Disease and the Toxic Food Supply

 

Robert H. Lustig, MD, MSL

Emeritus Professor of Pediatrics in the Division of Endocrinology
and Member of the Institute for Health Policy Studies at UCSF
University of California, San Francisco

 

Overview:

Mountain Dew Mouth has been the scourge of dentists for decades. But there’s a new disease which affects even more people: Mountain Dew Liver. Non-alcoholic fatty liver disease (NAFLD) wasn’t even discovered until 1980; and now up to 40% of Americans suffer from it, and it is now the leading cause of liver transplantation. Especially children – 13% of autopsies in children show NAFLD; and 38% of obese children. This disease belies all our other chronic diseases, including diabetes, heart disease, and cancer. And it is due to our excessive sugar consumption.  Dietary sugar is composed of one molecule each of glucose and fructose. It is the fructose that is the primary driver of both diseases.

 Objectives:

At the conclusion of the activity a participant should be able to:

  • Describe the effect of fluoride on cariogenesis, and its role as adjunct vs. primary prevention
  • Review how subcellular energy overload drives insulin resistance
  • Explain the differences and similarities between hepatic glucose vs. ethanol vs. fructose metabolism

Disclosures:

Robert H. Lustig, MD, MSL has nothing to disclose relevant to this program

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

December 2 | Howard A. Rockman, MD | G Protein-Coupled Receptors in Heart Failure: A Historical Perspective

Howard Rockman, MD, MSL

Edward S. Orgain Distinguished Professor of Cardiology in the School of Medicine, Professor of Medicine and Professor in Cell Biology at the Duke University School of Medicine

 

Overview:

A historical perspective of the discovery of the beta adrenergic receptor and mechanisms of GPCR signaling that has led to our current understanding of receptor signaling and how targeting GCPRs are used in the treatment of heart failure.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Recognize the mechanism of activation of G Protein-Coupled Receptors
  • Indicate the therapeutic role of G- Protein-Coupled Receptors in heart failure
  • Identify new concepts in G Protein-Coupled Receptor signaling

Disclosures:

Howard Rockman, MD, MSL has stock and is also a Scientific Co-Founder in Trevena Inc.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

December 9 | Jagmeet P. Singh, MD, PhD | Advances in Electrical Therapies for Heart Failure

Jagmeet P Singh, MD, PHD

Physician Investigator (Cl) at the Cardiovascular Research Center, Mass General Research Institute, Professor of Medicine at Harvard Medical School and Founding Director, Resynchronization and Advanced Cardiac Therapeutics Program at Mass General

Overview:

This presentation will discuss advances in cardiac resynchronization therapies, neuromodulation and other newer technologies for patients with advanced heart failure. It will also cover the importance of individualizing care, as well as providing multidisciplinary care to the advanced heart failure patient.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Demonstrate the newer technologies in promoting cardiac resynchronization
  • Describe the newer electrical therapies for the new narrow QRS patient
  • Distinguish the importance of multidisciplinary care for the heart failure patient an implanted device

Disclosures:

Jagmeet P Singh, MD, PHD is a consultant for Abbott, Boston Scientific, Biotronik M, Sanofi, Rhythm Management Group, Microport, Medtronic, EBR, and Cardiologs

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

THURSDAY January 12 | Tirone E. David, MD | Arrhythmogenic Mitral Valve: An Unresolved Health Problem | Ray C. Fish Award Presentation

Tirone E. David

Professor of Surgery at the University of Toronto
Melanie Munk Chair of Cardiovascular Surgery at the Peter Munk Cardiac Centre 

Overview:  

What surgical intervention has done for arrhythmogenic mitral regurgitation 

Objectives:  

At the conclusion of the activity a participant should be able to:  

  • Explain why rrhythmogenic mitral valve remains a serious and unresolved health problem 
  • Assess available approaches to reduce the risk of sudden death in patients with arrhythmogenic mitral valve 
  • Recognize Future directions on the identification and treatment of arrhythmogenic mitral valve. 

Disclosures: 

Tirone E. David, MD has nothing to disclose relevant to this program. 

The Planning Committee has nothing to disclose relevant to this program. 

The THI CME Staff has nothing to disclose relevant to this program. 

The Program Reviewers has nothing to disclose relevant to this program. 

Accreditation 

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

Credit Designation 

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

January 13 | Jihad Mustapha, MD, FACC, FSCAI | Critical Limb Ischemia and the Amputation Epidemic (Virtual)

Jihad A. Mustapha, MD

President & Chief Executive Officer, Director of Endovascular Interventions
Advanced Cardiovascular & Vascular Centers
Grand Rapids, MI

Overview:

Below the knee intervention options for best outcomes in CLI.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Summarize best diagnostic options for suspected CLI patients and importance of optimal medical therapy and ongoing surveillance in this patient population.
  • Summarize treatment options for patients with CLI
  • Determine treatment approach for patient presenting with CLI

Disclosures:

Jihad A. Mustapha, MD is a consultant for Bectin, Dickinson & Co (BD) and Angiodynamics; he is a Consultant/Researcher for Boston Scientific and Avinger

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

January 20 | Da-Zhi Wang, PhD, FAHA | Molecular Regulation of Cardiac Remodeling and Regeneration

Da-Zhi Wang, PhD

Professor of Internal Medicine and of Molecular Pharmacology and Physiology in the College of Medicine at the University of South Florida
Director of the Center for Regenerative Medicine at USF
Director of the USF Heart Institute

Overview:

  • Demonstrate genetic evidence to support the function of miRNAs in the heart
  • Critique basic molecular mechanism of how miRNAs work
  • Define how miRNAs and RBPs could become novel therapies for disease

Objectives:

At the conclusion of the activity a participant should be able to:

  • Knowledge of heart function and disease
  • Potential of novel therapeutic targets and strategies for heart disease
  • Animal models to study heart function and regeneration

Disclosures:

Da-Zhi Wang, PHD has nothing to disclose relevant to this program.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

January 27 | John Elrod, PhD | Metabolic Control of Fibroblast Fate and Cardiac Fibrosis

John Elrod, PhD

Director of the Cardiovascular Research Center in the Lewis Katz School of Medicine at Temple University

Overview:

We recently reported that glutaminolysis is essential for the epigenetic changes permissive to activation of the myofibroblast differentiation program and cardiac fibrosis. In fact, targeting these pathways is sufficient to reverse fibrosis in models of heart failure. These findings implicate metabolic remodeling as a critical feature of myofibroblast formation and persistence in the diseased heart. This presentation will highlight metabolite-dependent epigenetic signaling, new data implicating paracellular metabolic crosstalk as prominent mechanism in myofibroblast formation, and novel therapeutic targets in cardiac fibrosis and heart failure.

Objectives:

At the conclusion of the activity a participant should be able to:

  • Differentiate the role of fibroblast fate in the cardiac fibrotic response.
  • Define the molecular pathways underlying myofibroblast formation and persistence.
  • Summarize the basic metabolic underpinnings of fibroblast ECM deposition and function in the failing heart.

Disclosures:

John Elrod, PhD is a Paid consultant and SRA unrelated to current work for Mitobridge Inc., an Astellas Company. He is also an Consultant on projects unrelated to current work for Janssen, J&J.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

February 3 | Darren K. McGuire, MD, MHSc | Antihyperglycemic Medications for Cardiovascular Risk Reduction: A Cardiologist’s Perspective

Darren K. McGuire, MD

Professor in the Department of Internal Medicine at UT Southwestern Medical Center
Director of the Parkland Hospital and Health System Outpatient Cardiology clinics.

Overview:

Review of the regulatory landscape for drugs for type 2 diabetes and how recent and ongoing cardiovascular trials have impacted clinical care for patients with type 2 diabetes.

Objectives:

At the conclusion of the activity a participant should be able to:

  • To review the history of FDA regulation of drugs for type 2 diabetes
  • To summarize available data from completed CV outcomes trials in patients with type 2 diabetes.
  • To review contemporary specialty society recommendations and guidelines regarding the use of antihyperglycemic medications for cardiovascular and kidney disease risk mitigation

Disclosures:

Darren K. McGuire, MD, MHSc was an Honoraria for clinical trial leadership for Afimmune and Sanofi. He is currently an Honoraria for clinical trial leadership for Boehringer Ingelheim, Merck & Co, Pfizer, AstraZeneca, Novo Nordisk, Esperion, and Lilly US. Dr. McGuire was an Honoraria for consultancy for Merck & Co, Applied Therapeutics, Metavant, Sanofi, and Affimmune. He is still an Honoraria for consultancy for Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, GlaxoSmithKline, Lexicon, Altimmune, and Esperion. Dr. McGuire was an Honoraria for Expert Testimony for Kirkland & Ellis: for the benefit of Boehringer Ingelheim (2020); Teva Pharmaceuticals (2021)

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

February 10 | Sanjiv J. Shah, MD

February 17 | Morton J. Kern, MD, MSCAI, FAHA, FACC | (BCM Lewis Lectureship) Coronary Physiology in the Cath Lab and Beyond for 2023

Morton J Kern, MD

Professor of Medicine, University of California, Irvine School of Medicine

Chief of Medicine, VA Long Beach Health Care System

Overview:

Review the fundamentals of coronary pressure and flow

Address the invasive measurements of coronary physiology using sensor wires

Compare outcome studies using physiology to guide PCI

Objectives:

At the conclusion of the activity a participant should be able to:

  • Identify the fundamentals of coronary blood flow
  • Apply the invasive measurements of pressure and flow in the heart
  • Appreciate the outcome data using physiology to guide PCI

Disclosures:

Morton J Kern, MD is speaker for Abiomed, Abbott Vascular, Acist, Opsens, Phillips Inc., and Cathworks.

The Planning Committee has nothing to disclose relevant to this program.

The THI CME Staff has nothing to disclose relevant to this program.

The Program Reviewers has nothing to disclose relevant to this program.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

February 24 | NO GRAND ROUNDS | MCS Symposium and Critical Care Echo Workshop

March 3 | NO GRAND ROUNDS | ACC Meeting

March 10 | Henk L. Granzier, PhD

March 17 | TBA

March 24 | Jeffrey W. Olin, DO, FACC, FAHA, MSVM | Fibromuscular Dysplasia: The Rare Disease that Isn’t

March 31 | Reynolds Delgado, MD, FACC

April 7 | Pradeep Natarajan, MD (BCM Chapman Lectureship)

April 14 | NO GRAND ROUNDS | Echo Symposium

April 21 | Javed Butler, MD (BCM Dennis Lectureship)

April 28 | Ajith Nair, MD, FACC, FAHA | Innovations in Heart Failure

May 5 | TBA

May 12 | TBA

May 19 | Jennifer Lawton, MD

May 26 | Joseph Rogers, MD